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Abstract
Background: Prevalence of vancomycin-resistant enterococci has increased in Germany. Here, we report the cluster
of linezolid- and vancomycin-resistant Enterococcus faecium (LVRE) in a German department for hematologic stem
cell transplantation (HSCT).
Methods: In this retrospective analysis we included all patients with LVRE in a university-based department for HSCT in
2014 and 2015. Patients chart reviews were used to investigate the epidemiology and clinical outcome. Available LVRE
isolates underwent detailed microbiological characterization and genotyping by pulsed-field gel electrophoresis (PFGE).
Results: In total, 20 patients with LVRE were identified within the observed time period. All except two patients
underwent allogeneic HSCT. Surveillance culture results from incoming patients and chart review revealed that
10 of 20 patients were colonized at hospital admission. Eight of 10 patients with in-hospital acquired LVRE had
previous linezolid treatment. Analysis of spatio-temporal patterns showed no evidence for LVRE patient-to-patient
or environment-to-patient transmission within the HSCT department. In five cases (25 %) LVRE bloodstream infection
occurred. Nine LVRE isolates could be saved for characterization. Eight isolates carried vanA, one isolate vanB.
PFGE analysis showed that four different LVRE clones were responsible for the cluster. One single genotype was
present in six LVRE isolates whereupon the corresponding patients were all referred from the same hospital to
the HSCT department.
Conclusions: This is the first report demonstrating the emergence of LVRE in a German HSCT department. (L)VRE
screening at patients’ admission and appropriate infection control strategies were sufficient to prevent any transmission.
Further studies in this predisposed patient collective are warranted.
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Background
Data from 2014 of the European Antimicrobial Resistance
Surveillance Network (EARS-Net) reported the propor-
tion of vancomycin resistance in Enterococcus faecium in
Europe being 8.9 % [1]. The VRE rate in Germany has
increased dramatically in the last years [2]: Between 2007
and 2012 surgical site and bloodstream infections due to
VRE increased significantly (526 and 278 %) [2].
Infections with VRE are a major cause of morbidity in
HSCT recipients [3]. Universal use of central venous cath-
eters, heavy exposure to prophylactic and therapeutic
anti-infectives, numerous periods of hospitalization and
extensive contact to health-care providers predisposes this
patient cohort to colonization and subsequent infections
with resistant pathogens such as VRE [4].
Linezolid resistance in VRE (LVRE) is an uncommon
finding. Case reports and outbreaks of LVRE have been
* Correspondence: joerg.steinmann@uk-essen.de
5Institute of Medical Microbiology, University Hospital Essen, University
Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Krull et al. Antimicrobial Resistance and Infection Control  (2016) 5:31 
DOI 10.1186/s13756-016-0131-6
described from US, Greece, Italy and Ireland mainly in
intensive care unit patients, patients after solid organ
transplantation or with hematological malignancy [5–10].
Linezolid exposure and patient-to-patient transmission
were shown to be main factors for LVRE infection [11].
In this retrospective study (2014–2015) cases with LVRE
in a university-based HSCT department were reviewed to
understand the epidemiology. In addition, LVRE isolates
were characterized and genotyped to assess possible strain
transmission between patients.
Methods
Setting and patient population
The epidemiology of linezolid resistance in VRE was
investigated in the department for HSCT belonging to
the West German Cancer Center within the University
Hospital Essen over a period of 2 years (2014–2015).
The HSCT department provides specialist superregional
services for adult patients with hematological malignan-
cies. In 2014 and 2015 394 patients underwent allogeneic
HSCT. The clinic consists of three spatially separated
wards. The VRE rate (one isolate per patient) was in 2014
9.6 % and in 2015 15 %. All patients positive for LVRE and
with a stay in the HSCT department in the year 2014 and
2015 were included in the study. Patient chart review was
performed to retrieve clinical information from the
patients with LVRE.
Infection control measures
All incoming patients were screened for VRE by obtain-
ing rectal swabs or stool samples in outpatient facilities
before admission to the HSCT department. From every
hospitalized HSCT patient, surveillance cultures (rectal
swab/stool sample, urine, blood, respiratory secretions)
were weekly obtained. Infection control measures were
performed according to guidelines for preventing infectious
complications among hematopoietic cell transplant recipi-
ents: All patients were placed in single-patient rooms. The
rooms are protective environment rooms consisting with
high efficiency particulate air filter (HEPA). Standard
precautions include hand hygiene and wearing personal
protective equipment (gown, cap and gloves) were
recommended for hospital staff and visitors before
entering the room [12]. Environmental samples from
patient’s rooms (sink, shower etc.) were investigated on
a regular basis (every 4 weeks in each patient’s room)
for bacterial and fungal contamination. The swabs were
cultured on standard media (blood agar, MacConkey
agar, chromogenic Candida agar).
Bacterial isolation, identification and antibiotic-susceptibility
testing
Chromogenic medium (VRESelect, Bio-Rad, Munich,
Germany) selective for VRE was used for all rectal and
stool screening samples. Species identification was per-
formed by using MALDI-TOF mass spectrometry (VITEK
MS, bioMérieux, Nürtingen, Germany). Susceptibility test-
ing was conducted using the VITEK 2 system (bioMérieux)
and interpretation of clinical MIC breakpoints was per-
formed according to EUCAST. The MIC breakpoint of
linezolid according to EUCAST is > 4 μg/mL . For dapto-
mycin the breakpoint (>4 μg/ml) was used from CLSI. All
isolates with resistance against linezolid were confirmed by
linezolid MIC test strip (Liofilchem, Roseto degli Abruzzi,
Italy). Saved isolates were stored at −80 °C until further
characterization.
In total, nine isolates were available for further analyses at
the German Reference Center for Staphylococci and En-
terococci (Robert Koch Institute, Wernigerode, Germany).
There, antibiotic susceptibility testing was performed by
broth microdilution (BMD) as previously described [13].
Determination of van, virulence and cfr genes
PCR analysis for glycopeptide resistance genes (vanA and
vanB) and virulence markers (esp, hyl) was performed
using standard protocols [14]. Part of the cfr gene was
amplified as previously described [15]. Nucleotide changes
in 23S rDNA conferring linezolid resistance were deter-
mined and calculated using a previously described assay.
It is a combination of a PCR amplification of the six 23S
rDNA alleles in E. faecium followed by a restriction diges-
tion recognizing the mutated nucleotide position and a
subsequent gelchip-based separation of the digested vs.
non-digested fragments allowing a quantification [16].
Macrorestriction analysis
Macrorestriction analysis for the LVRE isolates were per-
formed using the restriction endonuclease SmaI with
subsequent PFGE as reported [13].
Statistics
Graphics were generated with GraphPad Prism (La Jolla,
USA).
Results
Characteristics of LVRE patients
In the observed time period, 20 patients were found to
be colonized or infected with LVRE in the HSCT depart-
ment. The percentage of LVRE among VRE in the HSCT
department was 27 % in 2014 and 20 % in 2015. All patient
characteristics are shown in Table 1. Eighteen of these 20
patients underwent HSCT; the two remaining patients had
a hematological malignancy with prolonged neutropenia. In
five cases (25 %) a bloodstream infection with LVRE oc-
curred. In two of the five cases (40 %) the LVRE bacteremia
was associated with death of the patient. In the other 15
cases, LVRE was predominantly found in the gut (positive
stool or rectal swab) or in the urinary tract. Overall, eight
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Linezolid Vancomycin Teicoplanin Daptomycin
1 M (66) lymphoma yes rectal no yes death A – – – – –
2 M (64) arthritis-metothrexat no urine no yes discharge unknown – – – – –
3 F (34) acute myeloic leukemia yes rectal, inguinal yes yes death C – – – – –
4 F (47) acute myeloic leukemia yes rectal, urine no unknwon discharge D – – – – –
5 M (70) acute myeloic leukemia yes rectal yes yes discharge E – – – – –
6 F (54) acute myeloic leukemia yes rectal, oral cavity, BAL no unknown death D – – – – –
7 F (48) myelodysplastic syndrome yes rectal, inguinal, wound yes yes death C 16 512 64 2 II
8 F (67) acute lymphatic leukemia yes anal, inguinal, oral cavity yes unknown discharge in
palliative care
D – – – – –
9 F (70) myelodysplastic syndrome yes rectal, armpit, urine no yes discharge D >32 512 128 2 I
10 F (68) aplastic anemia yes urine no unknown death D – – – – –
11 F (20) acute myeloic leukemia yes urine no unknown discharge D – – – – –
12 M (58) myelodysplastic syndrome yes rectal, inguinal no unknown discharge D 32 512 128 2 I
13 F (58) acute myeloic leukemia yes rectal, urine no unknown discharge D 16 512 128 2 I
14 M (53) acute myeloic leukemia yes rectal, hair yes no discharge D 16 512 128 4 I
15 F (10) histiocytosis yes rectal, urine no unknown discharge F – – – – –
16 F (22) acute myeloic leukemia yes rectal no no discharge D 16 512 128 2 I
17 M (62) acute myeloic leukemia yes rectal, oral cavity no unknown discharge D 16 512 128 2 I
18 M (57) acute myeloic leukemia yes rectal, urine no unknown death D – – – – –
19 F (70) acute myeloic leukemia yes rectal, oral cavity, urine no yes discharge G 32 512 128 2 IV
20 M (54) multiple myeloma no rectal no yes Discharge in
palliative care
H 16 1024 <1 2 III












patients died on the HSCT ward or were discharged into
palliative care (40 %).
Epidemiological investigations
Chart review revealed that all three spatially separated
wards were affected (Fig. 1). All LVRE patients stayed in
different patient rooms. Results from routine microbio-
logical surveillance swabs from the patient-near environ-
ment exhibit no LVRE (data not shown).
In 10 of 20 patients LVRE was found before or at date of
admission in the HSCT department. By analysis of the
hospitals from which the patients were referred, 12 of 20
patients were previously treated in hospital D (Table 1).
Based on the epidemiological analysis there was no evi-
dence for LVRE transmissions within the HSCT depart-
ment (Fig. 1). Pretreatment with linezolid before LVRE
detection could only be demonstrated for the patients
with LVRE acquisition during the hospital stay. Eight of 10
patients had prior linezolid therapy before LVRE detection
(Table 1).
Antimicrobial susceptibility profiles and molecular
characterization of LVRE
All 20 LVRE isolates had MICs for linezolid of ≥
16 mg/L. The in vitro activity using BMD method for
linezolid, vancomycin, teicoplanin and daptomycin
against the nine saved LVRE isolates are shown in
Table 1. All tested isolates were positive for esp and
two for hyl. Eight LVRE carried vanA, one isolate vanB
(patient number 20). PCR for cfr gene was negative for
all isolates. The most frequent resistance mechanism
in Enterococcus is a nucleotide change at position
2576 (G2576U) in the central region of domain V of
23S rRNA. All nine linezolid-resistant isolates pos-
sessed a combination of wildtype and mutated allele
variants typical for clinical enterococcal isolates show-
ing linezolid resistance.
PFGE typing
PFGE analysis of 9 LVRE isolates showed in total four
unrelated genotypes. In six isolates, one single clone
could be detected. These isolates belong to patients
that were treated in hospital D before admission to the
HSCT department. The three other LVRE were not
closely genetically related.
Discussion
To the best of our knowledge, this report constitutes the
first description of a cluster of LVRE in HSCT recipients
and shows also the first epidemiological data from
Germany.
One study reported that immunodeficiency, hematological
malignancy, hospitalization in a hematological ward and
prolonged antibiotic treatment have been identified as risk
factors for the development of linezolid resistance in
enterococci [7]. Furthermore, pre-treatment with linez-
olid was shown to select for LVRE [17]. However, LVRE
can also be found in patients without previous linezolid
therapy [18].
LVRE infections are a serious therapeutic challenge as
alternative antimicrobial agents are strongly limited.
Twenty-five percent of HSCT recipients had LVRE
bacteremia and 40 % of these were associated with fatal
outcome. Daptomycin as a new last resort antibiotic can be
in these cases one feasible option. According to the MIC-
breakpoint of CLSI for daptomycin (≤4 mg/L) all nine
LVRE isolates were susceptible to this antibiotic. It was re-
cently reported that Enterococcus faecium bacteremia with
increased daptomycin MICs (3–4 μg/mL) was shown to be
associated with predicted microbiological failure of dapto-
mycin therapy [19]. One of the isolates had a daptomycin
MIC of 4 mg/L.
The majority of our HSCT patients had multiple risk
factors for colonization and/or infection with (L)VRE.
Based on the epidemiological analyses and the VRE
screening results at admission we found that 60 % of
LVRE patients were referred from one specific hospital
(D) from which two-thirds had LVRE at the date of ad-
mission to the HSCT unit. Furthermore, the typing ana-
lyses showed that six of the nine saved LVRE isolates
were clonally related. The patients with these clones
were all pretreated in hospital D indicating that this
clonal cluster was brought into the HSCT department
from an external source.
In contrast, the identification of three other unrelated
LVRE genotypes from different patients underscores that
the cluster of LVRE was not only due to this “local out-
break in hospital D” but was rather a multifactorial event
of LVRE emergence in a high-risk patient collective. On
the one hand, LVRE emerged due to linezolid therapy
which received 8 of 10 patients without LVRE at admis-
sion. On the other hand, there were also independent
events of de novo selection of linezolid-resistant mutants
in VRE-positive patients.
Even though, the HSCT department was heavily af-
fected with LVRE patients we found no hints for trans-
mission between patients or from the environment to
the patients. The surveillance screening of all incoming
patients for (L)VRE for the early detection and prompt
initiation of hygienic barrier measures for all affected
patients may be the reason why there is no proof for
LVRE patient-to-patient transmission within the HSCT
department. Our study has some limitations. Firstly, it
was not possible to save all LVRE isolates of the af-
fected patients. Thus, the expressiveness concerning
the clonal spread is limited. Secondly, due to the retro-
spective study design we were not able to give enough
evidence for certain risk factors for LVRE colonization/
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Fig. 1 Epidemiological map of 20 patients with LVRE on three wards in the department of hematologic stem cell transplantation. For patient
number 6 the first detection of LVRE was already at the end of 2013. A stay in ambulance is only presented, if there was a detection of LVRE
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infection or treatment outcome in our HSCT recipi-
ents. Also, this is a case only study that has no com-
parison group. Further studies to identify risk factors
and to determine optimal treatment in this predisposed
high-risk patient collective are warranted.
Conclusions
In conclusion, LVRE emerged in HSCT recipients in a
German university hospital. Our study indicates that
(L)VRE screening at patients’ admission and appropriate
infection control strategies were sufficient to prevent
any intra-department transmissions.
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